Aphria Inc. (APHA)
(Delayed Data from NYSE)
$6.94 USD
-0.19 (-2.66%)
Updated May 3, 2019 04:02 PM ET
After-Market: $7.00 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.94 USD
-0.19 (-2.66%)
Updated May 3, 2019 04:02 PM ET
After-Market: $7.00 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Allscripts Unit Inks Deal to Boost Veradigm AccelRx Platform
by Zacks Equity Research
This deal is expected to bolster Allscripts' (MDRX) Clinical and Financial Solutions segment.
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about ResMed (RMD) on its focus on digital health technology and robust demand for its critical care products.
OPKO's BioReference Laboratories' Deal Brings Antibody Testing
by Zacks Equity Research
OPKO Health's (OPK) subsidiary, BioReference Laboratories collaborates with MagnaCare to offer antibody testing to Labor groups in New York metropolitan area.
Myriad's (MYGN) EndoPredict Grows Amid Coronavirus Mayhem
by Zacks Equity Research
Within Molecular Diagnostics, Myriad Genetics (MYGN) registers strong sales for EndoPredict, myChoice CDx and BRACAnalysis CDx.
Are Options Traders Betting on a Big Move in Aphria (APHA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Aphria (APHA) stock based on the movements in the options market lately.
Hologic's Second Molecular Test Gets EUA to Detect Coronavirus
by Zacks Equity Research
Hologic (HOLX) expects to boost testing capacity by combining its manufacturing ability for the latest EUA of test with its largest installed base of high-throughput molecular instruments.
Here's Why You Should Retain Masimo Stock (MASI) For Now
by Zacks Equity Research
Investor confidence remains high in Masimo (MASI) stock, thanks to solid prospects.
Here's Why You Should Retain Avanos Medical Stock for Now
by Zacks Equity Research
Avanos Medical (AVNS) continues to benefit from strong performing segments and robust product portfolio. However, stiff competition remains a concern.
Nevro's (NVRO) Senza Omnia SCS System Gets CE Mark Approval
by Zacks Equity Research
Nevro (NVRO) received CE mark approval for the Senza Omnia SCS system, which is likely to boost its international presence.
ResMed Grows on Solid Ventilator Sales Amid Coronavirus Woes
by Zacks Equity Research
ResMed (RMD) global sales increase on ramped-up demand for its critical care support products.
STERIS' (STE) Q4 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
STERIS' (STE) fourth-quarter fiscal 2020 results reflect strong segmental performance despite the coronavirus-led economic crisis.
GNC Holdings' (GNC) Q1 Earnings and Sales Miss Estimates
by Zacks Equity Research
All the operating segments of GNC Holdings (GNC) register significant year-over-year sales decline in Q1 on coronavirus-led business disruption.
AMN Healthcare (AMN) Q1 Earnings In Line With Estimates
by Zacks Equity Research
AMN Healthcare (AMN) gained from core operating segments in Q1.
Intersect ENT (XENT) Reports Wider-Than-Expected Q1 Loss
by Zacks Equity Research
Intersect ENT (XENT) performs disappointingly in the first quarter of 2020 due to the coronavirus crisis.
Here's Why You Should Retain Cardinal Health Stock for Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment, diversified product portfolio and strategic buyouts.
Phibro (PAHC) Q3 Earnings Surpass Estimates, Margin Declines
by Zacks Equity Research
Phibro (PAHC) witnessed revenue uptick in its core Animal Health segment in Q3 despite the coronavirus-led business disruptions in the animal production industry.
HMS Holdings (HMSY) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
HMS Holdings (HMSY) witnessed revenue growth at COB and PI segments in Q1.
Allscripts (MDRX) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Allscripts (MDRX) witnessed a decline in core Client Services and Software delivery unit revenues in Q1.
National Vision (EYE) Q1 Earnings Top Estimates, Margin Falls
by Zacks Equity Research
National Vision's (EYE) first-quarter 2020 results were better than expected despite the coronavirus-led economic crisis.
Integer Holdings (ITGR) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
Integer Holdings' (ITGR) first-quarter results benefit from strength in Cardio & Vascular sub-segment and margin expansion.
Zimmer Biomet (ZBH) Q1 Earnings Top, Revenues Miss Estimates
by Zacks Equity Research
The spread of coronavirus results in deferral of elective procedures for Zimmer Biomet (ZBH) in Q1.
Insulet (PODD) Q1 Earnings Lag Estimates, Margins Decline
by Zacks Equity Research
Insulet's (PODD) first-quarter 2020 results reflect mixed segmental performance amid the coronavirus-led economic crisis.
Fresenius Medical (FMS) Q1 Earnings Miss Estimates, Fall Y/Y
by Zacks Equity Research
Fresenius Medical's (FMS) first-quarter earnings benefit from strong segmental performance.
Cardinal Health (CAH) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Cardinal Health's (CAH) fiscal third-quarter results benefit from strong segmental performance.
LHC Group (LHCG) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
LHC Group (LHCG) continues to gain from home health services and hospice admissions, which improved year over year in Q1.